Intrahepatic Cholestasis of Pregnancy

Complex MONDO:0100429 Pathograph 12 Show in embeddings browser Pregnancy disorder Intrahepatic cholestasis

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-specific liver disorder, affecting roughly 0.2-2% of pregnancies. Genetically susceptible biliary transport (notably ABCB4, ABCB11 and ATP8B1 variants, and the wider bile-acid-synthesis and lipid-metabolism loci identified by genome-wide analysis) is unmasked by the high estrogen and progesterone metabolite load of the third trimester, impairing hepatocellular bile acid export. Maternal serum bile acids rise, producing the cardinal symptom of pruritus and raised aminotransferases. Bile acids cross the placenta and accumulate in the fetal compartment, where they disturb cardiomyocyte calcium handling and conduction; this is the leading mechanistic explanation for the sudden, unpredictable stillbirth that defines the clinical danger of the condition. Stillbirth risk is concentrated in women whose maximum total bile acid concentration reaches 100 micromol/L or more, which is why serial bile acid measurement rather than symptom severity drives management. Ursodeoxycholic acid is widely prescribed and is antiarrhythmic in fetal cardiac models, but the PITCHES randomised trial found no reduction in adverse perinatal outcomes, so timed delivery remains the principal risk-reduction strategy.

Ask OpenScientist

Ask a research question about Intrahepatic Cholestasis of Pregnancy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
5
Phenotypes
1
Hypotheses
2
Gaps
12
Pathograph
6
Genes
2
Medical Actions
5
References
🏷

Classifications

Harrison's Part
GASTROINTESTINAL
◈

Mechanistic Hypotheses

1
Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
fetal_bile_acid_cardiotoxicity_model CANONICAL
Evidence balance 2 support
ICP stillbirth is not caused by progressive placental insufficiency (which would be preceded by growth restriction and abnormal Dopplers) but by an acute, bile-acid-mediated fetal cardiac event. Bile acids transferred across the placenta accumulate in fetal serum and myocardium, where taurocholic acid disturbs cardiomyocyte calcium dynamics, slows conduction and promotes arrhythmia. This explains the characteristic clinical signature of ICP loss: sudden death in an appropriately grown fetus, near term, without antecedent surveillance abnormalities. It also explains why bile acid concentration rather than pruritus severity or transaminase level stratifies risk.
Strongest supporting strands are (1) the concentration-threshold epidemiology (stillbirth risk rises sharply at total bile acids of 100 micromol/L or more) and (2) direct cardiomyocyte electrophysiology in model systems. The principal gap is that the arrhythmia mechanism is demonstrated in rodent cardiomyocytes and in vitro human fetal cardiac cells, not in human fetuses in vivo, where the terminal event is by definition unobserved. See the HUMAN_MODEL_MISMATCH discussion below.
Pathograph links
Maternal Bile Acid Accumulation -> Transplacental Bile Acid Transfer and Fetal Accumulation DIRECT A maternal-to-fetal concentration gradient drives bile acid transfer across the placenta once maternal clearance is impaired.
Transplacental Bile Acid Transfer and Fetal Accumulation -> Fetal Cardiomyocyte Electrophysiological Disturbance DIRECT Fetal myocardial exposure to taurocholic acid and related bile acids perturbs calcium handling and conduction.
Fetal Cardiomyocyte Electrophysiological Disturbance -> Stillbirth INDIRECT KNOWN INTERMEDIATES A bile-acid-triggered fetal arrhythmia is the proposed terminal event in the sudden intrauterine death characteristic of severe ICP. Intermediates: fetal arrhythmia; fetal hypoxia
Show evidence (2 references)
PMID:30773280 SUPPORT Human Clinical
"The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more."
Individual-patient-data meta-analysis establishes the bile-acid concentration dependence of stillbirth risk, the epidemiological signature this model predicts.
PMID:26777584 SUPPORT In Vitro
"Bile acids are elevated in the blood of women with intrahepatic cholestasis of pregnancy (ICP) and this may lead to fetal arrhythmia, fetal hypoxia and potentially fetal death in utero."
States the fetal-arrhythmia route from maternal bile acid elevation to intrauterine death that this hypothesis group models.
?

Discussions and Knowledge Gaps

2
Bile-acid-induced cardiomyocyte calcium dysregulation and conduction slowing are demonstrated in neonatal rat cardiomyocytes and in in vitro human fetal cardiac cell models. Is a bile-acid-triggered arrhythmia the actual terminal event in human ICP stillbirth, or is the rodent and in vitro cardiotoxicity a model-system phenomenon that does not reproduce the in vivo human fetal myocardium at clinically observed bile acid concentrations?
HUMAN MODEL MISMATCH OPEN gap_icp_fetal_arrhythmia_human_translation
Attached to
pathophysiology#Fetal Cardiomyocyte Electrophysiological Disturbance pathophysiology#Transplacental Bile Acid Transfer and Fetal Accumulation phenotypes#Stillbirth
This is not an absence of evidence but a translational-validity question: positive mechanistic evidence exists in model systems, and the human epidemiology is strongly consistent with it (a sharp concentration threshold, sudden death in appropriately grown fetuses, no antecedent Doppler abnormality). What is missing is any direct in vivo human observation, because the terminal event is by definition unwitnessed and antenatal fetal ECG monitoring at the relevant moment is not feasible. The mismatch is mechanistically meaningful because rodent and human fetal myocardium differ in ion channel repertoire and in bile acid handling, and because the in vitro work uses taurocholic acid concentrations that may not reflect fetal myocardial exposure. Resolving it matters clinically: if the arrhythmia model is correct, an antiarrhythmic or bile-acid-lowering strategy could in principle avert stillbirth without iatrogenic prematurity, whereas if it is not, timed delivery remains the only lever. The negative PITCHES result is at least consistent with the possibility that lowering maternal bile acids pharmacologically does not reach the relevant fetal compartment.
Proposed experiments
Fetal compartment bile acid exposure and cardiac electrophysiology in human ICP
prospective mechanistic cohort study with human cardiac model arm Relation: this experiment is of type this experiment type This experiment is of type prospective mechanistic cohort study with human cardiac model arm.
exp_icp_fetal_myocardium_bile_acid_exposure
Pair cord-blood and amniotic-fluid bile acid speciation at delivery with antenatal fetal electrocardiographic or magnetocardiographic recording across the maternal bile acid range, including the 100 micromol/L or greater stratum. Test whether measurable conduction or repolarisation changes appear in human fetuses at the concentrations associated with excess stillbirth, and whether they track fetal rather than maternal bile acid concentration. Complement with human iPSC-derived fetal-like cardiomyocytes exposed to physiologically measured fetal bile acid concentrations and species mixtures rather than supraphysiological taurocholic acid alone.
Decision criterion
The model is supported if human fetal conduction or repolarisation abnormalities appear at fetal bile acid concentrations reached in severe ICP and scale with concentration. Absence of any electrophysiological signal across the full clinical range, despite confirmed fetal bile acid accumulation, would argue that the rodent and in vitro cardiotoxicity does not translate and would redirect the search for the terminal event.
Would support
pathophysiology#Fetal Cardiomyocyte Electrophysiological Disturbance
What is the quantified contribution of heterozygous ABCB4, ABCB11 and ATP8B1 variants to ICP susceptibility, relative to the polygenic bile-acid-synthesis and lipid-metabolism signal identified by genome-wide meta-analysis?
KNOWLEDGE GAP OPEN gap_icp_transporter_variant_evidence
Attached to
pathophysiology#Genetic and Hormonal Susceptibility of Hepatobiliary Transport
The genome-wide meta-analysis establishes these susceptibility signals at *locus* level - ABCB11 (2q31), ABCG5/8 (2p21), CYP8B1 (3p22) and ABCB1/4 (7q21) each reach genome-wide significance and are cited on the corresponding gene entries. What remains unquantified is the *variant* level: the contribution of individual rare heterozygous coding variants in ABCB4, ABCB11 and ATP8B1, which are curated here on the strength of the PFIC hepatology rather than ICP-specific effect sizes, and which a common-variant GWAS is not powered to resolve. Two further limits apply specifically to ABCB4: the 7q21 locus annotation does not discriminate it from the adjacent ABCB1, and ATP8B1 still carries no ICP-specific evidence item at all. Curation follow-up should attach variant-level citations (Dixon et al., reference 24 of PMID:42178310, is the obvious next fetch), or downgrade those gene entries if the effect sizes turn out to be small relative to the polygenic background.
⚙

Pathophysiology

5
Genetic and Hormonal Susceptibility of Hepatobiliary Transport
Heterozygous variants in canalicular transporter genes - ABCB4 (phospholipid floppase MDR3), ABCB11 (bile salt export pump BSEP) and ATP8B1 - reduce the reserve capacity of hepatocellular bile export without causing disease outside pregnancy. Genome-wide meta-analysis implicates a broader set of loci acting through bile acid synthesis and lipid metabolism. In the third trimester, sulfated progesterone metabolites and estrogen glucuronides inhibit BSEP and antagonise the bile acid sensor FXR (NR1H4), converting this latent reserve deficit into overt cholestasis. The strictly gestational timing of ICP, and its resolution after delivery, follow from this gene-by-hormone interaction.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
ABCB4 hgnc:45 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ABCB4 (hgnc:45). hgnc:45 is a gene from the HUGO Gene Nomenclature Committee. ABCB11 hgnc:42 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ABCB11 (hgnc:42). hgnc:42 is a gene from the HUGO Gene Nomenclature Committee. ATP8B1 hgnc:3706 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ATP8B1 (hgnc:3706). hgnc:3706 is a gene from the HUGO Gene Nomenclature Committee. NR1H4 hgnc:7967 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NR1H4 (hgnc:7967). hgnc:7967 is a gene from the HUGO Gene Nomenclature Committee.
response to estrogen GO:0043627 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to estrogen (GO:0043627). GO:0043627 is a biological process from the Gene Ontology. ↑ INCREASED bile acid metabolic process GO:0008206 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated bile acid metabolic process (GO:0008206). GO:0008206 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Impaired Hepatocellular Bile Acid Export Reduced transporter reserve, further inhibited by third-trimester sex steroid metabolites, lowers canalicular bile acid efflux capacity.
Show evidence (3 references)
PMID:42178310 SUPPORT Human Clinical
"The associated loci implicate bile acid synthesis, LDL cholesterol, and lipid metabolism."
GWAS meta-analysis of 4,738 cases anchors the genetic component of susceptibility in bile acid synthesis and lipid metabolism pathways.
PMID:42178310 SUPPORT Human Clinical
"Previous studies have implicated liver-enriched genes in intrahepatic cholestasis of pregnancy."
Supports a liver-intrinsic genetic contribution. The specific ABCB4/ABCB11/ATP8B1 transporter variants named in this node description are not individually enumerated in this snippet and would benefit from a dedicated citation.
PMID:42486596 SUPPORT Other
"Etiology is likely related to effects of estrogen and progesterone."
Review support for the sex-steroid arm of the gene-by-hormone interaction that makes this a pregnancy-restricted disorder.
Impaired Hepatocellular Bile Acid Export
Canalicular export of bile salts and phospholipid falls below the load presented to the hepatocyte, producing intrahepatic cholestasis with retention of bile acids inside the hepatocyte and a modest hepatocellular injury signature (raised aminotransferases). Unlike the biliary-obstruction cholestases, jaundice is uncommon and hepatic architecture is preserved, and the process reverses within days to weeks of delivery.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
bile acid and bile salt transport GO:0015721 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased bile acid and bile salt transport (GO:0015721). GO:0015721 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Maternal Bile Acid Accumulation Failure of hepatic clearance raises circulating total bile acid concentration.
Show evidence (1 reference)
PMID:42486596 SUPPORT Other
"Intrahepatic cholestasis of pregnancy is the most common liver disorder induced by pregnancy."
Establishes ICP as a hepatic cholestatic disorder of pregnancy.
Maternal Bile Acid Accumulation
Total serum bile acids rise, typically from the end of the second trimester. This is simultaneously the diagnostic biochemical abnormality, the driver of maternal pruritus, and - critically - the quantitative determinant of fetal risk. Because symptom intensity correlates poorly with concentration, serial quantitative bile acid measurement rather than clinical severity governs management.
Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
bile acid metabolic process GO:0008206 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated bile acid metabolic process (GO:0008206). GO:0008206 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Transplacental Bile Acid Transfer and Fetal Accumulation A maternal-to-fetal concentration gradient drives bile acid transfer across the placenta once maternal clearance is impaired. Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
Pruritus Retained bile acids and associated pruritogens activate cutaneous itch pathways, characteristically on the palms and soles and worse at night.
Show evidence (1 reference)
PMID:31378395 SUPPORT Human Clinical
"Intrahepatic cholestasis of pregnancy, characterised by maternal pruritus and increased serum bile acid concentrations, is associated with increased rates of stillbirth, preterm birth, and neonatal unit admission."
Links the maternal bile acid elevation to the pruritus phenotype and to the perinatal outcome set modeled downstream.
Transplacental Bile Acid Transfer and Fetal Accumulation
The fetus normally exports bile acids to the maternal circulation across the placenta. When the maternal compartment is loaded, this gradient flattens or reverses and bile acids accumulate in fetal serum, amniotic fluid and meconium. Fetal accumulation is the necessary link between a maternal hepatic disorder and a fetal cardiac event, and accounts for the meconium-stained liquor that accompanies severe disease.
Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
syncytiotrophoblast CL:0000525 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves syncytiotrophoblast, annotated with syncytiotrophoblast cell (CL:0000525). CL:0000525 is a cell type from the Cell Ontology.
bile acid and bile salt transport GO:0015721 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated bile acid and bile salt transport (GO:0015721). GO:0015721 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Fetal Cardiomyocyte Electrophysiological Disturbance Fetal myocardial exposure to taurocholic acid and related bile acids perturbs calcium handling and conduction. Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
Show evidence (1 reference)
PMID:26777584 SUPPORT In Vitro
"Bile acids are elevated in the blood of women with intrahepatic cholestasis of pregnancy (ICP) and this may lead to fetal arrhythmia, fetal hypoxia and potentially fetal death in utero."
Supports the maternal-bile-acid-to-fetal-harm axis. The snippet does not itself quantify transplacental transfer or fetal compartment concentrations, which remain to be cited directly.
Fetal Cardiomyocyte Electrophysiological Disturbance
Taurocholic acid produces abnormal calcium dynamics and impaired contraction in cardiomyocytes, slows ventricular conduction, and promotes arrhythmia. Cardiac fibroblast-cardiomyocyte coupling contributes: bile acids and hypoxia promote fibroblast-to-myofibroblast transition and gap-junctional depolarisation of cardiomyocytes, and ursodeoxycholic acid acts partly by hyperpolarising these myofibroblasts. This node is the mechanistic core of the stillbirth model and is where the human-translation uncertainty is concentrated.
Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
fetal cardiomyocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fetal cardiomyocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
cardiac muscle cell action potential GO:0086001 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cardiac muscle cell action potential (GO:0086001). GO:0086001 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Stillbirth A bile-acid-triggered fetal arrhythmia is the proposed terminal event in the sudden intrauterine death characteristic of severe ICP. Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
Show evidence (2 references)
PMID:26777584 SUPPORT In Vitro
"The bile acid taurocholic acid (TC) causes abnormal calcium dynamics and contraction in neonatal rat cardiomyocytes."
Direct cardiomyocyte-level evidence that the accumulating bile acid species disturbs excitation-contraction coupling.
PMID:26777584 SUPPORT In Vitro
"Ursodeoxycholic acid (UDCA), a drug clinically used to treat ICP, prevents adverse effects of TC."
Pharmacological rescue in the same system supports the causal direction from bile acid exposure to the cardiac disturbance.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Intrahepatic Cholestasis of Pregnancy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Integument 1
Pruritus OBLIGATE HP:0000989 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pruritus (HP:0000989). HP:0000989 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42486596 SUPPORT Other
"It is characterized by pruritus, with onset typically at the end of the second trimester."
Establishes pruritus as the defining symptom and its typical timing.
Metabolism 1
Elevated hepatic transaminases FREQUENT Elevated circulating hepatic transaminase concentration HP:0002910 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating hepatic transaminase concentration (HP:0002910). HP:0002910 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"Intrahepatic cholestasis of pregnancy, which affects 0.2-2% of pregnancies, is characterized by pruritus, increased aminotransferase activity and elevated serum bile acids."
Supports raised aminotransferase activity as a characteristic feature. The snippet does not quantify a frequency, so the FREQUENT band reflects general clinical description rather than this citation.
Prenatal and Birth 1
Premature birth FREQUENT HP:0001622 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Premature birth (HP:0001622). HP:0001622 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31378395 SUPPORT Human Clinical
"A systematic review and individual patient data meta-analysis1 from 2019 showed that intrahepatic cholestasis of pregnancy is associated with increased rates of spontaneous and iatrogenic preterm birth, meconium-stained amniotic fluid, and neonatal unit admission."
Documents both the spontaneous and iatrogenic components of preterm birth in ICP, as well as the meconium and neonatal-unit outcomes.
Other 2
Increased serum bile acid concentration OBLIGATE HP:0012202 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased serum bile acid concentration (HP:0012202). HP:0012202 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"Intrahepatic cholestasis of pregnancy, which affects 0.2-2% of pregnancies, is characterized by pruritus, increased aminotransferase activity and elevated serum bile acids."
Establishes elevated serum bile acids as a defining biochemical feature.
Stillbirth
No phenotype_term is asserted. HP:0003826 Stillbirth is a real HPO term but sits under Mortality/Aging and Prenatal death rather than under the HP:0000118 phenotypic-abnormality root, so it is outside the PhenotypeTerm dynamic enum, and MONDO has no stillbirth class. Binding to a coarser available parent would misrepresent the single most important outcome of this disorder, so the phenotype is left unbound and the ontology gap recorded here.
Show evidence (2 references)
PMID:30773280 SUPPORT Human Clinical
"The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more."
Establishes both the stillbirth association and its concentration threshold, the basis for bile-acid-guided delivery timing.
PMID:30773280 SUPPORT Human Clinical
"Because most women with intrahepatic cholestasis of pregnancy have bile acids below this concentration, they can probably be reassured that the risk of stillbirth is similar to that of pregnant women in the general population, provided repeat bile acid testing is done until delivery."
Documents that the excess stillbirth risk is confined to the severe tail, which is why the phenotype carries no overall frequency band.
🧬

Genetic Associations

6
ABCB4 (Susceptibility (heterozygous canalicular transporter variants))
Gene: ABCB4 hgnc:45 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ABCB4 (hgnc:45). hgnc:45 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"7q21 chr7:87487153 rs59934297 T/G 0.13 1.7E-49 0.60 (0.56-0.64) ABCB1/4"
Genome-wide significant ICP association (p=1.7e-49) at the 7q21 locus annotated to ABCB1/4, with the effect allele minor (frequency 0.13) and protective (OR 0.60, 95% CI 0.56-0.64). A second independent 7q21 signal (rs58238559, p=1.1e-17, OR 0.49) is reported in the same table. This is ICP-specific human genetic evidence at the 7q21 locus, distinct from the PFIC3 literature. Note the annotation names ABCB1 and ABCB4 jointly and does not resolve which of the two adjacent genes carries the signal.
ABCB11 (Susceptibility (bile salt export pump variants))
Gene: ABCB11 hgnc:42 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ABCB11 (hgnc:42). hgnc:42 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"2q31 chr2:169001056 rs6733156 C/T 0.07 7.6E-36 0.57 (0.53-0.63) ABCB11"
Genome-wide significant ICP association (p=7.6e-36) at the 2q31 locus for which ABCB11 is the annotated gene, with the minor allele protective (OR 0.57, 95% CI 0.53-0.63). This is ICP-specific human genetic evidence for BSEP involvement, distinct from the PFIC2 literature.
ATP8B1 (Susceptibility)
Gene: ATP8B1 hgnc:3706 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ATP8B1 (hgnc:3706). hgnc:3706 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
ABCG5 (Susceptibility (2p21 sterol-transport locus))
Gene: ABCG5 hgnc:13886 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ABCG5 (hgnc:13886). hgnc:13886 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"2p21 chr2:43844604 rs4148211 A/G 0.43 5.8E-113 0.61 (0.59-0.64) ABCG5/8"
Strongest ICP association in the meta-analysis (p=5.8e-113, OR 0.61, 95% CI 0.59-0.64) at the 2p21 locus annotated to the ABCG5/ABCG8 sterol transporter pair.
ABCG8 (Susceptibility (2p21 sterol-transport locus))
Gene: ABCG8 hgnc:13887 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ABCG8 (hgnc:13887). hgnc:13887 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
CYP8B1 (Susceptibility (3p22 bile-acid-synthesis locus))
Gene: CYP8B1 hgnc:2653 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CYP8B1 (hgnc:2653). hgnc:2653 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"3p22 chr3:42872353 rs12494055 T/C 0.49 1.2E-14 0.85 (0.81-0.88) CYP8B1"
Genome-wide significant ICP association (p=1.2e-14, OR 0.85, 95% CI 0.81-0.88) at the 3p22 locus annotated to CYP8B1, supporting a bile-acid-synthesis contribution to ICP susceptibility alongside the transporter loci.
💊

Medical Actions

2
Ursodeoxycholic Acid
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ursodeoxycholic acid CHEBI:9907 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ursodeoxycholic acid (CHEBI:9907). CHEBI:9907 is a therapeutic agent from Chemical Entities of Biological Interest.
A hydrophilic bile acid, historically the mainstay of ICP treatment. It reliably improves maternal pruritus and lowers biochemical markers, and is antiarrhythmic in fetal cardiac model systems. However the PITCHES randomised placebo-controlled trial found no reduction in the composite perinatal outcome of perinatal death, preterm birth or neonatal unit admission. UDCA is therefore best curated as a maternal symptomatic therapy with a mechanistically attractive but clinically unproven fetal-protective rationale.
Mechanism Target:
INHIBITS Fetal Cardiomyocyte Electrophysiological Disturbance — UDCA prevents taurocholic-acid-induced cardiomyocyte dysfunction in vitro, acting in part by hyperpolarising cardiac myofibroblasts. Note this target_mechanisms edge records the proposed mechanism of action, which the PITCHES trial did not translate into a perinatal outcome benefit.
Show evidence (3 references)
PMID:31378395 REFUTE Human Clinical
"Treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy."
The PITCHES randomised placebo-controlled trial refutes a perinatal-outcome benefit of UDCA, the claim on which its routine use had rested.
PMID:31378395 SUPPORT Human Clinical
"Ursodeoxycholic acid is widely used as a treatment without an adequate evidence base."
Documents that widespread clinical use preceded, and was not justified by, outcome evidence.
PMID:26777584 SUPPORT In Vitro
"Ursodeoxycholic acid (UDCA), a drug clinically used to treat ICP, prevents adverse effects of TC."
Supports the proposed fetal cardioprotective mechanism in vitro. This is mechanism-level, not outcome-level, support and does not offset the PITCHES result.
Bile-Acid-Guided Timed Delivery
Action: labor inductionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is labor induction, annotated with Induction of Labor (NCIT:C92814). NCIT:C92814 is a clinical intervention from the NCI Thesaurus. Ontology label: Induction of Labor NCIT:C92814
Because the stillbirth hazard is concentrated late in gestation and rises with bile acid concentration, planned early-term or preterm delivery timed to the maximum measured bile acid concentration is the principal intervention that plausibly reduces fetal death. This trades an iatrogenic prematurity cost against stillbirth risk, and the balance is explicitly concentration-dependent.
Show evidence (1 reference)
PMID:30773280 SUPPORT Human Clinical
"The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more."
Provides the concentration-threshold rationale for risk-stratified delivery timing. This is observational evidence for the risk gradient, not trial evidence that any particular delivery policy reduces stillbirth.
🔬

Biochemical Markers

1
Total serum bile acids (Elevated)
Context: Diagnostic and risk-stratifying measurement, repeated until delivery
Show evidence (1 reference)
PMID:30773280 SUPPORT Human Clinical
"In singleton pregnancies, stillbirth was associated with maximum total bile acid concentration"
Shows that stillbirth risk tracks the maximum total bile acid concentration, justifying bile-acid-led monitoring. The same sentence reports that alanine aminotransferase does not discriminate (ROC AUC 0.46), which is why transaminases are not used for risk stratification; that clause is omitted from the quoted snippet only because its bracketed confidence intervals break substring matching.
📊

Prevalence

1
Pregnancies (Finnish, Icelandic, Estonian and Danish biobank cohorts)
Period Prevalence 200.0–2000.0 per 100,000 >1 in 1,000
0.2-2% of pregnancies (200-2,000 per 100,000). Modeled as a period prevalence across the pregnancy episode. Incidence varies substantially by ancestry and geography, being notably higher in Chile and in South Asian populations.
Show evidence (1 reference)
PMID:42178310 SUPPORT Human Clinical
"Intrahepatic cholestasis of pregnancy, which affects 0.2-2% of pregnancies, is characterized by pruritus, increased aminotransferase activity and elevated serum bile acids."
Provides the per-pregnancy occurrence range used for this record.
{ }

Source YAML

click to show 
name: Intrahepatic Cholestasis of Pregnancy
creation_date: "2026-08-02T00:00:00Z"
category: Complex
synonyms:
- ICP
- Obstetric cholestasis
- Cholestasis of pregnancy
description: >-
  Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-specific
  liver disorder, affecting roughly 0.2-2% of pregnancies. Genetically susceptible
  biliary transport (notably ABCB4, ABCB11 and ATP8B1 variants, and the wider
  bile-acid-synthesis and lipid-metabolism loci identified by genome-wide analysis)
  is unmasked by the high estrogen and progesterone metabolite load of the third
  trimester, impairing hepatocellular bile acid export. Maternal serum bile acids
  rise, producing the cardinal symptom of pruritus and raised aminotransferases.
  Bile acids cross the placenta and accumulate in the fetal compartment, where they
  disturb cardiomyocyte calcium handling and conduction; this is the leading
  mechanistic explanation for the sudden, unpredictable stillbirth that defines the
  clinical danger of the condition. Stillbirth risk is concentrated in women whose
  maximum total bile acid concentration reaches 100 micromol/L or more, which is why
  serial bile acid measurement rather than symptom severity drives management.
  Ursodeoxycholic acid is widely prescribed and is antiarrhythmic in fetal cardiac
  models, but the PITCHES randomised trial found no reduction in adverse perinatal
  outcomes, so timed delivery remains the principal risk-reduction strategy.
disease_term:
  preferred_term: intrahepatic cholestasis of pregnancy
  term:
    id: MONDO:0100429
    label: intrahepatic cholestasis of pregnancy
parents:
- Pregnancy disorder
- Intrahepatic cholestasis
classifications:
  harrisons_chapter:
  - classification_value: GASTROINTESTINAL
prevalence:
- population: Pregnancies (Finnish, Icelandic, Estonian and Danish biobank cohorts)
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 200.0
  rate_high: 2000.0
  notes: >-
    0.2-2% of pregnancies (200-2,000 per 100,000). Modeled as a period prevalence
    across the pregnancy episode. Incidence varies substantially by ancestry and
    geography, being notably higher in Chile and in South Asian populations.
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intrahepatic cholestasis of pregnancy, which affects 0.2-2% of pregnancies, is characterized by pruritus, increased aminotransferase activity and elevated serum bile acids."
    explanation: Provides the per-pregnancy occurrence range used for this record.
mechanistic_hypotheses:
- hypothesis_group_id: fetal_bile_acid_cardiotoxicity_model
  hypothesis_label: Fetal Bile Acid Cardiotoxicity Model of ICP Stillbirth
  status: CANONICAL
  description: >-
    ICP stillbirth is not caused by progressive placental insufficiency (which would
    be preceded by growth restriction and abnormal Dopplers) but by an acute,
    bile-acid-mediated fetal cardiac event. Bile acids transferred across the
    placenta accumulate in fetal serum and myocardium, where taurocholic acid
    disturbs cardiomyocyte calcium dynamics, slows conduction and promotes
    arrhythmia. This explains the characteristic clinical signature of ICP loss:
    sudden death in an appropriately grown fetus, near term, without antecedent
    surveillance abnormalities. It also explains why bile acid concentration rather
    than pruritus severity or transaminase level stratifies risk.
  notes: >-
    Strongest supporting strands are (1) the concentration-threshold epidemiology
    (stillbirth risk rises sharply at total bile acids of 100 micromol/L or more)
    and (2) direct cardiomyocyte electrophysiology in model systems. The principal
    gap is that the arrhythmia mechanism is demonstrated in rodent cardiomyocytes
    and in vitro human fetal cardiac cells, not in human fetuses in vivo, where the
    terminal event is by definition unobserved. See the HUMAN_MODEL_MISMATCH
    discussion below.
  evidence:
  - reference: PMID:30773280
    reference_title: "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more."
    explanation: >-
      Individual-patient-data meta-analysis establishes the bile-acid concentration
      dependence of stillbirth risk, the epidemiological signature this model predicts.
  - reference: PMID:26777584
    reference_title: "The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Bile acids are elevated in the blood of women with intrahepatic cholestasis of pregnancy (ICP) and this may lead to fetal arrhythmia, fetal hypoxia and potentially fetal death in utero."
    explanation: >-
      States the fetal-arrhythmia route from maternal bile acid elevation to
      intrauterine death that this hypothesis group models.
pathophysiology:
- name: Genetic and Hormonal Susceptibility of Hepatobiliary Transport
  biological_scale: MOLECULAR
  description: >-
    Heterozygous variants in canalicular transporter genes - ABCB4 (phospholipid
    floppase MDR3), ABCB11 (bile salt export pump BSEP) and ATP8B1 - reduce the
    reserve capacity of hepatocellular bile export without causing disease outside
    pregnancy. Genome-wide meta-analysis implicates a broader set of loci acting
    through bile acid synthesis and lipid metabolism. In the third trimester,
    sulfated progesterone metabolites and estrogen glucuronides inhibit BSEP and
    antagonise the bile acid sensor FXR (NR1H4), converting this latent reserve
    deficit into overt cholestasis. The strictly gestational timing of ICP, and its
    resolution after delivery, follow from this gene-by-hormone interaction.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  genes:
  - preferred_term: ABCB4
    term:
      id: hgnc:45
      label: ABCB4
  - preferred_term: ABCB11
    term:
      id: hgnc:42
      label: ABCB11
  - preferred_term: ATP8B1
    term:
      id: hgnc:3706
      label: ATP8B1
  - preferred_term: NR1H4
    term:
      id: hgnc:7967
      label: NR1H4
  biological_processes:
  - preferred_term: response to estrogen
    modifier: INCREASED
    term:
      id: GO:0043627
      label: response to estrogen
  - preferred_term: bile acid metabolic process
    modifier: DYSREGULATED
    term:
      id: GO:0008206
      label: bile acid metabolic process
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The associated loci implicate bile acid synthesis, LDL cholesterol, and lipid metabolism."
    explanation: >-
      GWAS meta-analysis of 4,738 cases anchors the genetic component of susceptibility
      in bile acid synthesis and lipid metabolism pathways.
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Previous studies have implicated liver-enriched genes in intrahepatic cholestasis of pregnancy."
    explanation: >-
      Supports a liver-intrinsic genetic contribution. The specific ABCB4/ABCB11/ATP8B1
      transporter variants named in this node description are not individually
      enumerated in this snippet and would benefit from a dedicated citation.
  - reference: PMID:42486596
    reference_title: "Intrahepatic Cholestasis of Pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Etiology is likely related to effects of estrogen and progesterone."
    explanation: >-
      Review support for the sex-steroid arm of the gene-by-hormone interaction that
      makes this a pregnancy-restricted disorder.
  downstream:
  - target: Impaired Hepatocellular Bile Acid Export
    description: >-
      Reduced transporter reserve, further inhibited by third-trimester sex steroid
      metabolites, lowers canalicular bile acid efflux capacity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - sulfated progesterone metabolite inhibition of BSEP
    - FXR antagonism reducing transporter transcription
- name: Impaired Hepatocellular Bile Acid Export
  conforms_to: "cholestatic_liver_injury#Impaired Bile Formation and Secretion"
  biological_scale: CELLULAR
  description: >-
    Canalicular export of bile salts and phospholipid falls below the load presented
    to the hepatocyte, producing intrahepatic cholestasis with retention of bile
    acids inside the hepatocyte and a modest hepatocellular injury signature
    (raised aminotransferases). Unlike the biliary-obstruction cholestases, jaundice
    is uncommon and hepatic architecture is preserved, and the process reverses
    within days to weeks of delivery.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: bile acid and bile salt transport
    modifier: DECREASED
    term:
      id: GO:0015721
      label: bile acid and bile salt transport
  evidence:
  - reference: PMID:42486596
    reference_title: "Intrahepatic Cholestasis of Pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Intrahepatic cholestasis of pregnancy is the most common liver disorder induced by pregnancy."
    explanation: Establishes ICP as a hepatic cholestatic disorder of pregnancy.
  downstream:
  - target: Maternal Bile Acid Accumulation
    description: Failure of hepatic clearance raises circulating total bile acid concentration.
    causal_link_type: DIRECT
- name: Maternal Bile Acid Accumulation
  conforms_to: "cholestatic_liver_injury#Hepatocellular and Biliary Bile Acid Retention"
  biological_scale: ORGANISM
  description: >-
    Total serum bile acids rise, typically from the end of the second trimester.
    This is simultaneously the diagnostic biochemical abnormality, the driver of
    maternal pruritus, and - critically - the quantitative determinant of fetal
    risk. Because symptom intensity correlates poorly with concentration, serial
    quantitative bile acid measurement rather than clinical severity governs
    management.
  biological_processes:
  - preferred_term: bile acid metabolic process
    modifier: DYSREGULATED
    term:
      id: GO:0008206
      label: bile acid metabolic process
  evidence:
  - reference: PMID:31378395
    reference_title: "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intrahepatic cholestasis of pregnancy, characterised by maternal pruritus and increased serum bile acid concentrations, is associated with increased rates of stillbirth, preterm birth, and neonatal unit admission."
    explanation: >-
      Links the maternal bile acid elevation to the pruritus phenotype and to the
      perinatal outcome set modeled downstream.
  downstream:
  - target: Transplacental Bile Acid Transfer and Fetal Accumulation
    description: >-
      A maternal-to-fetal concentration gradient drives bile acid transfer across the
      placenta once maternal clearance is impaired.
    hypothesis_groups:
    - fetal_bile_acid_cardiotoxicity_model
    causal_link_type: DIRECT
  - target: Pruritus
    description: >-
      Retained bile acids and associated pruritogens activate cutaneous itch
      pathways, characteristically on the palms and soles and worse at night.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Transplacental Bile Acid Transfer and Fetal Accumulation
  biological_scale: ORGANISM
  description: >-
    The fetus normally exports bile acids to the maternal circulation across the
    placenta. When the maternal compartment is loaded, this gradient flattens or
    reverses and bile acids accumulate in fetal serum, amniotic fluid and meconium.
    Fetal accumulation is the necessary link between a maternal hepatic disorder and
    a fetal cardiac event, and accounts for the meconium-stained liquor that
    accompanies severe disease.
  cell_types:
  - preferred_term: syncytiotrophoblast
    term:
      id: CL:0000525
      label: syncytiotrophoblast cell
  biological_processes:
  - preferred_term: bile acid and bile salt transport
    modifier: DYSREGULATED
    term:
      id: GO:0015721
      label: bile acid and bile salt transport
  evidence:
  - reference: PMID:26777584
    reference_title: "The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Bile acids are elevated in the blood of women with intrahepatic cholestasis of pregnancy (ICP) and this may lead to fetal arrhythmia, fetal hypoxia and potentially fetal death in utero."
    explanation: >-
      Supports the maternal-bile-acid-to-fetal-harm axis. The snippet does not itself
      quantify transplacental transfer or fetal compartment concentrations, which
      remain to be cited directly.
  downstream:
  - target: Fetal Cardiomyocyte Electrophysiological Disturbance
    description: >-
      Fetal myocardial exposure to taurocholic acid and related bile acids perturbs
      calcium handling and conduction.
    hypothesis_groups:
    - fetal_bile_acid_cardiotoxicity_model
    causal_link_type: DIRECT
- name: Fetal Cardiomyocyte Electrophysiological Disturbance
  biological_scale: CELLULAR
  description: >-
    Taurocholic acid produces abnormal calcium dynamics and impaired contraction in
    cardiomyocytes, slows ventricular conduction, and promotes arrhythmia. Cardiac
    fibroblast-cardiomyocyte coupling contributes: bile acids and hypoxia promote
    fibroblast-to-myofibroblast transition and gap-junctional depolarisation of
    cardiomyocytes, and ursodeoxycholic acid acts partly by hyperpolarising these
    myofibroblasts. This node is the mechanistic core of the stillbirth model and is
    where the human-translation uncertainty is concentrated.
  cell_types:
  - preferred_term: fetal cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cardiac muscle cell action potential
    modifier: ABNORMAL
    term:
      id: GO:0086001
      label: cardiac muscle cell action potential
  evidence:
  - reference: PMID:26777584
    reference_title: "The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The bile acid taurocholic acid (TC) causes abnormal calcium dynamics and contraction in neonatal rat cardiomyocytes."
    explanation: >-
      Direct cardiomyocyte-level evidence that the accumulating bile acid species
      disturbs excitation-contraction coupling.
  - reference: PMID:26777584
    reference_title: "The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Ursodeoxycholic acid (UDCA), a drug clinically used to treat ICP, prevents adverse effects of TC."
    explanation: >-
      Pharmacological rescue in the same system supports the causal direction from
      bile acid exposure to the cardiac disturbance.
  downstream:
  - target: Stillbirth
    description: >-
      A bile-acid-triggered fetal arrhythmia is the proposed terminal event in the
      sudden intrauterine death characteristic of severe ICP.
    hypothesis_groups:
    - fetal_bile_acid_cardiotoxicity_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - fetal arrhythmia
    - fetal hypoxia
phenotypes:
- name: Pruritus
  category: Dermatological
  frequency: OBLIGATE
  diagnostic: true
  description: >-
    Intense itching without a primary rash, classically involving the palms and
    soles and worse at night, beginning most often at the end of the second
    trimester. It is the presenting symptom and is required for the diagnosis, but
    its severity does not track bile acid concentration or fetal risk.
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: PMID:42486596
    reference_title: "Intrahepatic Cholestasis of Pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It is characterized by pruritus, with onset typically at the end of the second trimester."
    explanation: Establishes pruritus as the defining symptom and its typical timing.
- name: Increased serum bile acid concentration
  category: Biochemical
  frequency: OBLIGATE
  diagnostic: true
  description: >-
    Raised total serum bile acids define the diagnosis alongside pruritus and are the
    only measurement that stratifies fetal risk.
  phenotype_term:
    preferred_term: Increased serum bile acid concentration
    term:
      id: HP:0012202
      label: Increased serum bile acid concentration
  reports_on:
  - target: Maternal Bile Acid Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Serum total bile acid concentration directly measures the accumulation node and
      is the basis of risk stratification and delivery timing.
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intrahepatic cholestasis of pregnancy, which affects 0.2-2% of pregnancies, is characterized by pruritus, increased aminotransferase activity and elevated serum bile acids."
    explanation: Establishes elevated serum bile acids as a defining biochemical feature.
- name: Elevated hepatic transaminases
  category: Biochemical
  frequency: FREQUENT
  description: Raised alanine and aspartate aminotransferase reflecting hepatocellular stress.
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intrahepatic cholestasis of pregnancy, which affects 0.2-2% of pregnancies, is characterized by pruritus, increased aminotransferase activity and elevated serum bile acids."
    explanation: >-
      Supports raised aminotransferase activity as a characteristic feature. The
      snippet does not quantify a frequency, so the FREQUENT band reflects general
      clinical description rather than this citation.
- name: Stillbirth
  category: Obstetric
  description: >-
    Sudden intrauterine fetal death, typically late in the third trimester and
    typically in an appropriately grown fetus without preceding surveillance
    abnormality. Risk is concentrated in women whose maximum total bile acid
    concentration reaches 100 micromol/L or more; below 40 micromol/L the risk
    approximates the background population rate.
  notes: >-
    No phenotype_term is asserted. HP:0003826 Stillbirth is a real HPO term but sits
    under Mortality/Aging and Prenatal death rather than under the HP:0000118
    phenotypic-abnormality root, so it is outside the PhenotypeTerm dynamic enum, and
    MONDO has no stillbirth class. Binding to a coarser available parent would
    misrepresent the single most important outcome of this disorder, so the phenotype
    is left unbound and the ontology gap recorded here.
  evidence:
  - reference: PMID:30773280
    reference_title: "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more."
    explanation: >-
      Establishes both the stillbirth association and its concentration threshold, the
      basis for bile-acid-guided delivery timing.
  - reference: PMID:30773280
    reference_title: "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because most women with intrahepatic cholestasis of pregnancy have bile acids below this concentration, they can probably be reassured that the risk of stillbirth is similar to that of pregnant women in the general population, provided repeat bile acid testing is done until delivery."
    explanation: >-
      Documents that the excess stillbirth risk is confined to the severe tail, which
      is why the phenotype carries no overall frequency band.
- name: Premature birth
  category: Obstetric
  frequency: FREQUENT
  description: >-
    Both spontaneous preterm labour and iatrogenic preterm delivery undertaken to
    pre-empt stillbirth. The iatrogenic component means preterm birth rates in ICP
    partly reflect management policy rather than disease biology alone.
  phenotype_term:
    preferred_term: Premature birth
    term:
      id: HP:0001622
      label: Premature birth
  evidence:
  - reference: PMID:31378395
    reference_title: "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A systematic review and individual patient data meta-analysis1 from 2019 showed that intrahepatic cholestasis of pregnancy is associated with increased rates of spontaneous and iatrogenic preterm birth, meconium-stained amniotic fluid, and neonatal unit admission."
    explanation: >-
      Documents both the spontaneous and iatrogenic components of preterm birth in ICP,
      as well as the meconium and neonatal-unit outcomes.
biochemical:
- name: Total serum bile acids
  presence: Elevated
  context: Diagnostic and risk-stratifying measurement, repeated until delivery
  notes: >-
    The single most important measurement in ICP. Risk stratification uses the maximum
    antenatal value: below 40 micromol/L the stillbirth risk approximates background;
    40-99 micromol/L is intermediate; 100 micromol/L or more carries a markedly
    elevated risk and prompts earlier delivery.
  evidence:
  - reference: PMID:30773280
    reference_title: "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In singleton pregnancies, stillbirth was associated with maximum total bile acid concentration"
    explanation: >-
      Shows that stillbirth risk tracks the maximum total bile acid concentration,
      justifying bile-acid-led monitoring. The same sentence reports that alanine
      aminotransferase does not discriminate (ROC AUC 0.46), which is why transaminases
      are not used for risk stratification; that clause is omitted from the quoted
      snippet only because its bracketed confidence intervals break substring matching.
genetic:
- name: ABCB4
  gene_term:
    preferred_term: ABCB4
    term:
      id: hgnc:45
      label: ABCB4
  association: Susceptibility (heterozygous canalicular transporter variants)
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    Encodes MDR3, the canalicular phospholipid floppase. Biallelic loss causes
    progressive familial intrahepatic cholestasis type 3; heterozygous carriage
    reduces biliary phospholipid reserve and predisposes to ICP when the
    third-trimester sex steroid load is applied. Two independent 7q21 signals reach
    genome-wide significance in the ICP meta-analysis, so the association is
    established at locus level; the locus annotation is 'ABCB1/4' and does not
    discriminate between the adjacent ABCB1 and ABCB4 genes, and the effect of
    individual rare heterozygous coding variants against that polygenic background
    remains open (see the discussions block).
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "7q21 chr7:87487153 rs59934297 T/G 0.13 1.7E-49 0.60 (0.56-0.64) ABCB1/4"
    explanation: >-
      Genome-wide significant ICP association (p=1.7e-49) at the 7q21 locus annotated
      to ABCB1/4, with the effect allele minor (frequency 0.13) and protective
      (OR 0.60, 95% CI 0.56-0.64). A second independent 7q21 signal (rs58238559,
      p=1.1e-17, OR 0.49) is reported in the same table. This is ICP-specific human
      genetic evidence at the 7q21 locus, distinct from the PFIC3 literature. Note
      the annotation names ABCB1 and ABCB4 jointly and does not resolve which of the
      two adjacent genes carries the signal.
- name: ABCB11
  gene_term:
    preferred_term: ABCB11
    term:
      id: hgnc:42
      label: ABCB11
  association: Susceptibility (bile salt export pump variants)
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    Encodes BSEP, the rate-limiting canalicular bile salt export pump and the direct
    target of inhibitory sulfated progesterone metabolites. The 2q31 locus reaches
    genome-wide significance in the ICP meta-analysis, so the association is
    established at locus level; the effect of individual rare heterozygous coding
    variants against that polygenic background remains open (see the discussions
    block).
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "2q31 chr2:169001056 rs6733156 C/T 0.07 7.6E-36 0.57 (0.53-0.63) ABCB11"
    explanation: >-
      Genome-wide significant ICP association (p=7.6e-36) at the 2q31 locus for which
      ABCB11 is the annotated gene, with the minor allele protective (OR 0.57,
      95% CI 0.53-0.63). This is ICP-specific human genetic evidence for BSEP
      involvement, distinct from the PFIC2 literature.
- name: ATP8B1
  gene_term:
    preferred_term: ATP8B1
    term:
      id: hgnc:3706
      label: ATP8B1
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    Encodes FIC1; biallelic loss causes progressive familial intrahepatic cholestasis
    type 1, and heterozygous variants are reported in ICP. No ICP-specific evidence
    item is attached yet.
- name: ABCG5
  gene_term:
    preferred_term: ABCG5
    term:
      id: hgnc:13886
      label: ABCG5
  association: Susceptibility (2p21 sterol-transport locus)
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    ABCG5 and its head-to-head partner ABCG8 encode the heterodimeric canalicular
    sterol efflux transporter. The 2p21 lead variant rs4148211 is the strongest
    signal in the ICP meta-analysis by several orders of magnitude, placing sterol
    export - not only bile salt export - in the susceptibility architecture. The
    locus is annotated ABCG5/8 and does not resolve to one of the pair.
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "2p21 chr2:43844604 rs4148211 A/G 0.43 5.8E-113 0.61 (0.59-0.64) ABCG5/8"
    explanation: >-
      Strongest ICP association in the meta-analysis (p=5.8e-113, OR 0.61,
      95% CI 0.59-0.64) at the 2p21 locus annotated to the ABCG5/ABCG8 sterol
      transporter pair.
- name: ABCG8
  gene_term:
    preferred_term: ABCG8
    term:
      id: hgnc:13887
      label: ABCG8
  association: Susceptibility (2p21 sterol-transport locus)
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    Obligate heterodimer partner of ABCG5; curated alongside it because the 2p21
    locus annotation does not discriminate between the two adjacent genes. See the
    ABCG5 entry for the shared locus evidence.
- name: CYP8B1
  gene_term:
    preferred_term: CYP8B1
    term:
      id: hgnc:2653
      label: CYP8B1
  association: Susceptibility (3p22 bile-acid-synthesis locus)
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    Sterol 12-alpha-hydroxylase, which sets the cholic to chenodeoxycholic acid
    ratio and therefore the hydrophobicity of the circulating bile acid pool. A
    synthesis-side susceptibility locus, complementing the transport-side ABCB4 /
    ABCB11 / ABCG5-8 signals.
  evidence:
  - reference: PMID:42178310
    reference_title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "3p22 chr3:42872353 rs12494055 T/C 0.49 1.2E-14 0.85 (0.81-0.88) CYP8B1"
    explanation: >-
      Genome-wide significant ICP association (p=1.2e-14, OR 0.85, 95% CI 0.81-0.88)
      at the 3p22 locus annotated to CYP8B1, supporting a bile-acid-synthesis
      contribution to ICP susceptibility alongside the transporter loci.
treatments:
- name: Ursodeoxycholic Acid
  description: >-
    A hydrophilic bile acid, historically the mainstay of ICP treatment. It reliably
    improves maternal pruritus and lowers biochemical markers, and is antiarrhythmic
    in fetal cardiac model systems. However the PITCHES randomised placebo-controlled
    trial found no reduction in the composite perinatal outcome of perinatal death,
    preterm birth or neonatal unit admission. UDCA is therefore best curated as a
    maternal symptomatic therapy with a mechanistically attractive but clinically
    unproven fetal-protective rationale.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Fetal Cardiomyocyte Electrophysiological Disturbance
    treatment_effect: INHIBITS
    description: >-
      UDCA prevents taurocholic-acid-induced cardiomyocyte dysfunction in vitro,
      acting in part by hyperpolarising cardiac myofibroblasts. Note this
      target_mechanisms edge records the proposed mechanism of action, which the
      PITCHES trial did not translate into a perinatal outcome benefit.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ursodeoxycholic acid
      term:
        id: CHEBI:9907
        label: ursodeoxycholic acid
  evidence:
  - reference: PMID:31378395
    reference_title: "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy."
    explanation: >-
      The PITCHES randomised placebo-controlled trial refutes a perinatal-outcome
      benefit of UDCA, the claim on which its routine use had rested.
  - reference: PMID:31378395
    reference_title: "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ursodeoxycholic acid is widely used as a treatment without an adequate evidence base."
    explanation: >-
      Documents that widespread clinical use preceded, and was not justified by,
      outcome evidence.
  - reference: PMID:26777584
    reference_title: "The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Ursodeoxycholic acid (UDCA), a drug clinically used to treat ICP, prevents adverse effects of TC."
    explanation: >-
      Supports the proposed fetal cardioprotective mechanism in vitro. This is
      mechanism-level, not outcome-level, support and does not offset the PITCHES result.
- name: Bile-Acid-Guided Timed Delivery
  description: >-
    Because the stillbirth hazard is concentrated late in gestation and rises with
    bile acid concentration, planned early-term or preterm delivery timed to the
    maximum measured bile acid concentration is the principal intervention that
    plausibly reduces fetal death. This trades an iatrogenic prematurity cost against
    stillbirth risk, and the balance is explicitly concentration-dependent.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: labor induction
    term:
      id: NCIT:C92814
      label: Induction of Labor
  evidence:
  - reference: PMID:30773280
    reference_title: "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more."
    explanation: >-
      Provides the concentration-threshold rationale for risk-stratified delivery
      timing. This is observational evidence for the risk gradient, not trial evidence
      that any particular delivery policy reduces stillbirth.
discussions:
- discussion_id: gap_icp_fetal_arrhythmia_human_translation
  prompt: >-
    Bile-acid-induced cardiomyocyte calcium dysregulation and conduction slowing are
    demonstrated in neonatal rat cardiomyocytes and in in vitro human fetal cardiac
    cell models. Is a bile-acid-triggered arrhythmia the actual terminal event in
    human ICP stillbirth, or is the rodent and in vitro cardiotoxicity a
    model-system phenomenon that does not reproduce the in vivo human fetal
    myocardium at clinically observed bile acid concentrations?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Fetal Cardiomyocyte Electrophysiological Disturbance
  - pathophysiology#Transplacental Bile Acid Transfer and Fetal Accumulation
  - phenotypes#Stillbirth
  rationale: >-
    This is not an absence of evidence but a translational-validity question: positive
    mechanistic evidence exists in model systems, and the human epidemiology is
    strongly consistent with it (a sharp concentration threshold, sudden death in
    appropriately grown fetuses, no antecedent Doppler abnormality). What is missing is
    any direct in vivo human observation, because the terminal event is by definition
    unwitnessed and antenatal fetal ECG monitoring at the relevant moment is not
    feasible. The mismatch is mechanistically meaningful because rodent and human fetal
    myocardium differ in ion channel repertoire and in bile acid handling, and because
    the in vitro work uses taurocholic acid concentrations that may not reflect fetal
    myocardial exposure. Resolving it matters clinically: if the arrhythmia model is
    correct, an antiarrhythmic or bile-acid-lowering strategy could in principle avert
    stillbirth without iatrogenic prematurity, whereas if it is not, timed delivery
    remains the only lever. The negative PITCHES result is at least consistent with the
    possibility that lowering maternal bile acids pharmacologically does not reach the
    relevant fetal compartment.
  proposed_experiments:
  - experiment_id: exp_icp_fetal_myocardium_bile_acid_exposure
    name: Fetal compartment bile acid exposure and cardiac electrophysiology in human ICP
    description: >-
      Pair cord-blood and amniotic-fluid bile acid speciation at delivery with
      antenatal fetal electrocardiographic or magnetocardiographic recording across the
      maternal bile acid range, including the 100 micromol/L or greater stratum. Test
      whether measurable conduction or repolarisation changes appear in human fetuses
      at the concentrations associated with excess stillbirth, and whether they track
      fetal rather than maternal bile acid concentration. Complement with human
      iPSC-derived fetal-like cardiomyocytes exposed to physiologically measured fetal
      bile acid concentrations and species mixtures rather than supraphysiological
      taurocholic acid alone.
    experiment_type:
      preferred_term: prospective mechanistic cohort study with human cardiac model arm
    decision_criterion: >-
      The model is supported if human fetal conduction or repolarisation abnormalities
      appear at fetal bile acid concentrations reached in severe ICP and scale with
      concentration. Absence of any electrophysiological signal across the full
      clinical range, despite confirmed fetal bile acid accumulation, would argue that
      the rodent and in vitro cardiotoxicity does not translate and would redirect the
      search for the terminal event.
    would_support:
    - pathophysiology#Fetal Cardiomyocyte Electrophysiological Disturbance
- discussion_id: gap_icp_transporter_variant_evidence
  prompt: >-
    What is the quantified contribution of heterozygous ABCB4, ABCB11 and ATP8B1
    variants to ICP susceptibility, relative to the polygenic bile-acid-synthesis and
    lipid-metabolism signal identified by genome-wide meta-analysis?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Genetic and Hormonal Susceptibility of Hepatobiliary Transport
  rationale: >-
    The genome-wide meta-analysis establishes these susceptibility signals at
    *locus* level - ABCB11 (2q31), ABCG5/8 (2p21), CYP8B1 (3p22) and ABCB1/4 (7q21)
    each reach genome-wide significance and are cited on the corresponding gene
    entries. What remains unquantified is the *variant* level: the contribution of
    individual rare heterozygous coding variants in ABCB4, ABCB11 and ATP8B1, which
    are curated here on the strength of the PFIC hepatology rather than ICP-specific
    effect sizes, and which a common-variant GWAS is not powered to resolve. Two
    further limits apply specifically to ABCB4: the 7q21 locus annotation does not
    discriminate it from the adjacent ABCB1, and ATP8B1 still carries no ICP-specific
    evidence item at all. Curation follow-up should
    attach variant-level citations (Dixon et al., reference 24 of PMID:42178310, is
    the obvious next fetch), or downgrade those gene entries if the effect sizes turn
    out to be small relative to the polygenic background.
references:
- reference: PMID:42486596
  title: "Intrahepatic Cholestasis of Pregnancy."
- reference: PMID:42178310
  title: "Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy."
- reference: PMID:30773280
  title: "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses."
- reference: PMID:31378395
  title: "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial."
- reference: PMID:26777584
  title: "The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts."
📚

References & Deep Research

References

5
PMID:42486596
Intrahepatic Cholestasis of Pregnancy.
No top-level findings curated for this source.
PMID:42178310
Genome-wide meta-analysis identifies genetic drivers of bile acid metabolism in intrahepatic cholestasis of pregnancy.
No top-level findings curated for this source.
PMID:30773280
Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.
No top-level findings curated for this source.
PMID:31378395
Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
No top-level findings curated for this source.
PMID:26777584
The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts.
No top-level findings curated for this source.